Volume 5 Supplement 1

Proceedings of the 12-th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)

Open Access

Risk of HIV-associated Hodgkin lymphoma during the first months after initiation of combination antiretroviral therapy

  • E Lanoy1Email author,
  • PS Rosenberg2,
  • F Fily3,
  • AS Lascaux4,
  • V Martinez5,
  • M Partisani6,
  • I Poizot-Martin7,
  • E Rouveix8,
  • EA Engels2,
  • D Costagliola1, 9 and
  • JJ Goedert2
Infectious Agents and Cancer20105(Suppl 1):A71

DOI: 10.1186/1750-9378-5-S1-A71

Published: 11 October 2010


Since the advent of combination antiretroviral therapy (cART), several studies have described an increase in the incidence of Hodgkin lymphoma (HL). This increase has been postulated to be linked with immunologic mechanisms occurring at cART initiation. Relationships between the CD4 cell count and the risk of HL have also been investigated. Our study aimed to evaluate the risk of HL by use of cART and its duration.

Materials and methods

From the French Hospital Database on HIV (FHDH-ANRS CO4), a large prospective hospital cohort, we studied the incidence of HL in 1992-2007 according to the duration of cART exposure: no cART and year<1996, no cART and year ≥1996, [0;1], [1;2], [2;3], [3;6] and ≥6 months. Relative rates (RR) of HL were estimated using Poisson regression models for the duration of cART exposure, adjusted for age, period of followup, sex and exposure group, migration from sub-Saharan Africa, AIDS stage, and CD4 cell count.


Our study included 286,806 person-years (PY) of followup and 187 HL cases. The incidence of HL was not associated with the period: 0.79, 0.60, and 0.64 per 1000 PY before 1996, in 1996-1999, and since 2000, respectively (p=0.55). Risk of HL was significantly related to cART (p=0.008), being especially high during the first 3 months of use (Table 1). The association remained after adjustment for age, sex and exposure group, migration, and AIDS stage (p=0.006), but not in the model accounting for CD4 cell count (p=0.058). A peak of HL incidence was observed for 50-99 CD4 cell count and the association between risk of HL and CD4 cell count remained significant in the multivariate model (Figure 1, p<10-6).
Table 1



No of diagnoses

Incidence per 1000 PY

Crude RR 95%CI

Adjusted RR Model 1* 95%CI

Adjusted Model 2** 95%CI

no cART and year<1996



1.35 [0.84;2.18]

1.14 [0.7;1.85]

0.68 [0.4;1.17]

no cART and year>=1996









3.48 [1.48;8.17]

3.09 [1.31;7.28]

1.75 [0.73;4.19]




1.19 [0.29;4.89]

1.05 [0.25;4.33]

0.30 [0.04;2.23]




4.11 [1.85;9.13]

3.62 [1.62;8.08]

2.17 [0.96;4.92]




1.63 [0.76;3.46]

1.43 [0.67;3.05]

0.90 [0.41;1.94]




1.00 [0.69;1.43]

0.83 [0.57;1.2]

0.75 [0.51;1.10]

*adjusted for age, sex and exposure group, migration for sub-Saharan Africa, AIDS stage. **adjusted for variables in model 1 and CD4 cell count.

Figure 1



Our results support that the early cART effect on the risk of HL is largely explained by CD4 count.



This abstract is presented on behalf of the FHDH-ANRS CO4.

This article has been published as part of Infectious Agents and Cancer Volume 5 Supplement 1, 2010: Proceedings of the 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI).The full contents of the supplement are available online at http://www.biomedcentral.com/1750-9378/5?issue=S1.

Authors’ Affiliations

INSERM, U943, Paris, France; UPMC Univ Paris 06
Division of Cancer Epidemiology and Genetics, National Cancer Institute
Service des Maladies Infectieuses et de Réanimation Médicale, CHU Pontchaillou
Département d’immunologie clinique, Hôpital Henri-Mondor
Service de Médecine Interne, AP-HP, Hôpital Antoine Béclère
Centre de soins de l’infection à VIH, Hôpitaux Universitaires
Unité CISIH Sud Hématologie VIH, Hôpital Sainte-Marguerite
Service de Médecine 5, Hôpital Ambroise-Paré
Service de Maladies Infectieuses et Tropicales, AP-HP, Groupe hospitalier Pitié-Salpêtrière


© Lanoy et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.